Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 19/20 | 1.00 |
| ▸ | PKLR | P30613 | 9/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30621218 | 1.00 | PKM (1.00) | PKMPKLRNPC1RAB9AALDH1A1 | |
| SCHEMBL30621219 | 1.00 | PKM (1.00) | PKMPKLRNPC1RAB9AALDH1A1 | |
| SCHEMBL15746503 | 0.96 | PKM (1.00) | PKMPKLRNPC1RAB9AALDH1A1 | |
| SCHEMBL12354636 | 0.88 | PKM (1.00) | PKMPKLRNPC1RAB9AALDH1A1 | |
| SCHEMBL12346542 | 0.86 | PKM (0.74) | PKMPKLRNPC1RAB9AALDH1A1 | |
| SCHEMBL13431990 | 0.84 | PKM (1.00) | PKMPKLRNPC1RAB9AALDH1A1 | |
| SCHEMBL1722758 | 0.84 | PKM (1.00) | PKMPKLRNPC1RAB9AALDH1A1 | |
| SCHEMBL14872086 | 0.83 | PKM (0.71) | PKMPKLRNPC1RAB9AALDH1A1 | |
| SCHEMBL1725568 | 0.83 | PKM (1.00) | PKMPKLRNPC1RAB9AALDH1A1 | |
| SCHEMBL1719967 | 0.81 | PKM (1.00) | PKMPKLRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230215-A1 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUT5) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-07-17 | — | — | US | claimed |
| WO-2025137634-A1 | COMPOSITIONS AND METHODS OF TARGETING PYRUVATE KINASE ISOFORM M2 (PKM2) | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025059108-A1 | THERAPEUTIC COMBINATION AND USE THEREOF FOR TREATING CANCER BY MANIPULATING PYRUVATE KINASE ACTIVITY AND INHIBITING CYSTEINE/CYSTINE METABOLISM | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-03-20 | — | — | WO | claimed |
| EP-4429676-A2 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUTS) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | Memorial Sloan Kettering Cancer Center (US) | 2024-09-18 | — | — | EP | claimed |
| CN-117442729-A | Inhibiting ARRB1 function for treating gastric cancer | 北京市肿瘤防治研究所 | 2024-01-26 | — | — | CN | claimed |
| WO-2023191515-A1 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH COMPRISING INDIRUBIN DERIVATIVE AND METABOLIC ACTIVATOR | 연세대학교 산학협력단 | 2023-10-05 | — | — | WO | claimed |
| WO-2023081455-A2 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUTS) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-05-11 | — | — | WO | claimed |
| CN-110951707-B | Pyruvate kinase M2 mutant and application thereof in cardiovascular diseases | 南京医科大学 | 2022-11-11 | — | — | CN | claimed |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12448367-B2 | Phthalazine derivatives as pyruvate kinase modulators | SITRYX THERAPEUTICS LIMITED (GB) | 2025-10-21 | — | — | US | disclosed |
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2025-09-18 | — | — | US | disclosed |
| EP-4612132-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-20250230143-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2012151450-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US Dept. of Health and Human Services (US) | 2011-08-11 | — | — | US | disclosed |
| WO-2010042867-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | PDK1, PDK2, PDK4 | PKM 13/4885PKLR 16/4885NPC1 2172/4885 |
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | GLUL, GGT1, GLS | PKM 793/4885PKLR 442/4885NPC1 3998/4885 |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 5/4885PKLR 7/4885NPC1 4729/4885 |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PKLR | PKM 6/4885PKLR 3/4885NPC1 2897/4885 |
| US-20250230143-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | PDK1, PDK2, PDK3 | PKM 8/4885PKLR 12/4885NPC1 2065/4885 |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | GSTP1, GSTK1, GSTM1 | PKM 3769/4885PKLR 2994/4885NPC1 1796/4885 |
| US-20250230215-A1 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUT5) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | SLC2A1, SLC2A2, SLC2A3 | PKM 838/4885PKLR 817/4885NPC1 357/4885 |
| US-12448367-B2 | Phthalazine derivatives as pyruvate kinase modulators | PDK1, PDK2, PDK3 | PKM 8/4885PKLR 12/4885NPC1 2065/4885 |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885PKLR 7/4885NPC1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.